Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 0.02% | -21.23% | -17.45% | -13.63% | 4.89% |
| Total Depreciation and Amortization | -0.33% | 36.71% | 48.69% | 15.99% | 7.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.30% | 22.72% | 9.06% | 25.23% | -5.14% |
| Change in Net Operating Assets | -152.58% | 55.91% | 58.53% | -3,960.57% | 92.26% |
| Cash from Operations | -1.59% | -8.08% | 7.98% | -63.84% | 17.96% |
| Capital Expenditure | -177.45% | 81.22% | 23.32% | 35.14% | 3.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -187.94% | -- | 100.00% | -- | -100.00% |
| Cash from Investing | -617.00% | 83.10% | 61.55% | 33.07% | -115.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2,791.67% | 0.00% | 0.00% | -4.35% | 0.00% |
| Issuance of Common Stock | 51.24% | 1,311.41% | 95.84% | -98.68% | 6,140.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 50.02% | 1,319.73% | 97.03% | -98.69% | 6,201.07% |
| Foreign Exchange rate Adjustments | 207.83% | -163.54% | 9,150.00% | 99.35% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 121.50% | 70.07% | 14.57% | -181.44% | 11,979.74% |